07.10.2015

ARS regulatory team submitted a package for approval of an open-label, randomized, crossover study of the comparative pharmacokinetics and bioequivalence of Levofloxacin generic developed by the Russian pharmaceutical company. The drug is applied for the treatment of bacterial infection diseases.